# A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

> **NCT05583955** · PHASE2 · COMPLETED · sponsor: **Noema Pharma AG** · enrollment: 75 (actual)

## Conditions studied

- Childhood-Onset Fluency Disorder

## Interventions

- **DRUG:** NOE-105
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05583955
- **Lead sponsor:** Noema Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-25
- **Primary completion:** 2023-10-20
- **Final completion:** 2023-11-24
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05583955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05583955, "A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05583955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*